PITTSBURGH, July 29, 2026
Viatris Inc. has received U.S. Food and Drug Administration (FDA) approval for Gwyn Lo™ (norelgestromin and ethinyl estradiol transdermal system), a once-weekly, low-dose estrogen contraceptive patch designed to expand contraceptive options for women of childbearing potential. Approved through the FDA’s 505(b)(2) regulatory pathway, the innovative transdermal system provides a non-invasive, reversible combined hormonal contraceptive (CHC) option for women with a body mass index (BMI) below 30 kg/m² who are appropriate candidates for hormonal contraception. Supported by positive results from the Phase 3 Luminous Study, the approval marks an important milestone in Viatris’ women’s health portfolio, reinforcing the company’s commitment to delivering innovative therapies that improve patient choice, convenience, and long-term reproductive healthcare. The company expects Gwyn Lo™ to become commercially available later this year, offering healthcare providers and patients a new once-weekly contraceptive solution with demonstrated efficacy, reliable patch adhesion, and a well-characterized safety profile.
FDA Approval Expands Women’s Contraceptive Choices
The approval of Gwyn Lo™ introduces a new once-weekly transdermal contraceptive patch that delivers norelgestromin 220 mcg/day and ethinyl estradiol 20 mcg/day, providing a lower-dose estrogen alternative within the combined hormonal contraceptive category. Unlike daily oral contraceptives, the patch is applied once each week for three consecutive weeks, followed by one patch-free week, simplifying treatment adherence while maintaining effective pregnancy prevention. Developed for women who prefer a non-invasive, reversible contraceptive method, Gwyn Lo combines convenience with consistent drug delivery through an advanced multilayer transdermal system. The approval strengthens Viatris’ long-standing focus on women’s health, while addressing the continued need for additional contraceptive choices that accommodate varying patient lifestyles, treatment preferences, and reproductive healthcare goals. As demand grows for personalized contraceptive solutions, the introduction of a low-dose weekly patch expands options available to clinicians and patients alike.
Phase 3 Study Demonstrates Strong Clinical Performance
The FDA approval was supported by data from the Phase 3 Luminous Study, which evaluated the contraceptive efficacy, safety, and real-world performance of Gwyn Lo™. The clinical trial demonstrated a Pearl Index of 4.14, confirming effective pregnancy prevention among women aged 18 to 35 years. Researchers also reported excellent patch adhesion, with only 1.3% of nearly 40,000 patches applied during the year-long study becoming fully detached. Additional findings showed that rates of unscheduled bleeding gradually declined throughout treatment, while the most commonly reported adverse events included mild application site irritation, erythema, pruritus, nausea, and intercycle bleeding. Separate Phase 1 investigations further confirmed consistent drug delivery under various real-world conditions, including exercise, sauna exposure, whirlpool use, and cold-water immersion, demonstrating reliable transdermal performance across everyday activities.
Strengthening Innovation in Women’s Health
The approval of Gwyn Lo™ represents another significant advancement in Viatris’ global women’s healthcare strategy, expanding its portfolio of therapies focused on improving reproductive health and patient access to innovative treatment options. With unintended pregnancy continuing to represent an important public health challenge, expanding contraceptive choices remains essential for supporting individualized patient care and informed clinical decision-making. The once-weekly transdermal system combines pharmaceutical innovation with patient convenience, offering healthcare professionals another evidence-based option that may improve treatment adherence compared with daily contraceptive methods. As Viatris continues investing in innovative medicines, transdermal drug delivery technologies, and patient-centered healthcare solutions, the FDA approval of Gwyn Lo™ reinforces the company’s commitment to advancing women’s health, improving reproductive care, and delivering high-quality therapies that address evolving clinical needs worldwide.
Source: Viatris press release



